A recombinant triplebody with specificity for CD19 and HLA-DR mediates preferential binding to antigen double-positive cells by dual-targeting.
about
T cell-recruiting triplebody 19-3-19 mediates serial lysis of malignant B-lymphoid cells by a single T cellNK cells from an AML patient have recovered in remission and reached comparable cytolytic activity to that of a healthy monozygotic twin mediated by the single-chain triplebody SPM-2.A dual-targeting triplebody mediates preferential redirected lysis of antigen double-positive over single-positive leukemic cells.Efficient targeting of CD13 on cancer cells by the immunotoxin scFv13-ETA' and the bispecific scFv [13xds16].Simultaneous targeting of prostate stem cell antigen and prostate-specific membrane antigen improves the killing of prostate cancer cells using a novel modular T cell-retargeting system.CD19-specific triplebody SPM-1 engages NK and γδ T cells for rapid and efficient lysis of malignant B-lymphoid cells.Enhanced tumor-targeting selectivity by modulating bispecific antibody binding affinity and format valence.Dual-targeting triplebody 33-3-19 mediates selective lysis of biphenotypic CD19+ CD33+ leukemia cells.Clinical safety and pharmacological profile of the HLA-DR antibody 1D09C3 in patients with B cell chronic lymphocytic leukemia and lymphoma: results from a phase I study.Trispecific antibodies for CD16A-directed NK cell engagement and dual-targeting of tumor cells.Generation of BiKEs and TriKEs to Improve NK Cell-Mediated Targeting of Tumor Cells.Natural killer cells unleashed: Checkpoint receptor blockade and BiKE/TriKE utilization in NK-mediated anti-tumor immunotherapy.Dual-targeting triplebody 33-16-123 (SPM-2) mediates effective redirected lysis of primary blasts from patients with a broad range of AML subtypes in combination with natural killer cells
P2860
Q34227769-25C59F90-304D-4AFF-A152-F832AD322744Q37348420-520A52A3-376B-45BE-BFE1-2BDB5C37CF11Q37593702-31D43776-C056-4F49-9D76-6B93E2614BBCQ38698179-89B552F5-1715-4684-88FA-59D9118BF7E1Q38972576-81C345EB-23D5-46FE-A8A8-E428808CEC44Q39204394-BDC83510-5EB6-49F3-87A3-385CB2048117Q40971778-C4E72E2E-73D0-4B3E-A1AC-FCF29738F3C8Q40996964-73EAEB7D-6372-4F60-BD3A-994752260978Q44797709-735A509F-0483-4C11-8B01-DC0DF3E5C4A6Q47691851-7432FB7D-D086-4DD9-A0F1-382194149088Q50042227-0A886B6C-0907-4C79-AA18-C4DC60AB0B96Q50204340-5FBA7659-91C6-4C38-A882-D06B5C09D2BBQ57174193-D3EC9F67-DFB1-4439-8FA5-FEF3FF445696
P2860
A recombinant triplebody with specificity for CD19 and HLA-DR mediates preferential binding to antigen double-positive cells by dual-targeting.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
A recombinant triplebody with ...... itive cells by dual-targeting.
@en
A recombinant triplebody with ...... itive cells by dual-targeting.
@nl
type
label
A recombinant triplebody with ...... itive cells by dual-targeting.
@en
A recombinant triplebody with ...... itive cells by dual-targeting.
@nl
prefLabel
A recombinant triplebody with ...... itive cells by dual-targeting.
@en
A recombinant triplebody with ...... itive cells by dual-targeting.
@nl
P2093
P2860
P356
P1476
A recombinant triplebody with ...... sitive cells by dual-targeting
@en
P2093
Andreas Mackensen
Bernhard Stockmeyer
Christian Berens
Christoph Stein
Domenica Saul
Fuat S Oduncu
Georg H Fey
Ingo Schubert
Markus Kügler
Michael Schwenkert
P2860
P356
10.4161/MABS.4.1.18498
P577
2012-01-01T00:00:00Z